A new pharmaceutical candidate enters Lundbeck's development pipeline

H. Lundbeck A/S (Lundbeck) strengthens its pipeline of pharmaceuticals in
clinical development by initiating clinical phase I studies with Lu AF11167 in
order to investigate safety, tolerability and the pharmacokinetic profile of the
drug in humans.

Lu AF11167 is a new compound inhibiting a phosphodiesterase enzyme primarily
expressed in brain and here in regions relevant for a number of both
neurological and psychiatric diseases in humans. By inhibiting this enzyme, Lu
AF11167 boosts signalling and thus increases the activity of certain neurons in
the brain.

Extensive research in animals suggests that these type of compounds have
potential in e.g. Alzheimer's disease, Huntington's chorea and schizophrenia.

"Our Focus at Lundbeck Research is to discover innovative compounds that address
unmet needs in patients with CNS diseases. Lu AF11167 is an example of a new
generation of compounds with a great potential for treatment of certain CNS
conditions currently inadequately treated," says Executive Vice President Peter
Høngaard Andersen, Head of Research at Lundbeck.

Financial guidance
The content of this release will have no influence on the Lundbeck Group's
financial guidance for 2011 which was provided on 24 February 2011 in connection
with the release of the financial results for 2010.



Lundbeck contacts

Investors:                           Media:



Palle Holm Olesen                    Mads Kronborg

Chief Specialist, Investor Relations Media Relations Manager

+45 36 43 24 26                      +45 36 43 28 51



Magnus Thorstholm Jensen             Stine Hove Marsling

Investor Relations Officer           External Communication Specialist

+45 36 43 38 16                      +45 36 43 28 33



Jacob Tolstrup

Vice President

+1 847 282 5713


About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical
company highly committed to improving the quality of life for people suffering
from central nervous system (CNS) disorders. For this purpose, Lundbeck is
engaged in the research, development, production, marketing and sale of
pharmaceuticals across the world. The company's products are targeted at
disorders such as depression and anxiety, schizophrenia, insomnia, epilepsy and
Huntington's, Alzheimer's and Parkinson's diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today
Lundbeck employs approximately 5,900 people worldwide. Lundbeck is one of the
world's leading pharmaceutical companies working with CNS disorders. In 2010,
the company's revenue was DKK 14.8 billion (approximately EUR 2.0 billion or USD
2.6 billion). For more information, please visit www.lundbeck.com.


[HUG#1500893]